Renale Denervation – Auswirkung auf Blutdruck und HbA_1c

Die renale Denervation ist für Patienten mit therapierefraktärer arterieller Hypertonie eine sichere Therapieoption. In offenen randomisierten Studien konnte in Praxismessungen eine signifikante Blutdruckreduktion um 32 ± 12 mmHg nachgewiesen werden, im klinischen Alltag wird eine Blutdruckreduktion bei ca. 70 % der behandelten Patienten beobachtet. Einzelne Untersuchungen zeigen eine Verringerung der Sympathikusaktivität. Positive Einflüsse auf den Glukosemetabolismus werden diskutiert.

Renal denervation offers a safe catheter-based approach for reduction of renal sympathetic drive. Based on present evidence, it appears to be indicated for the treatment of resistant hypertension. More studies are needed to assess its role in the management of less servere forms of hypertension and conditions driven by sympathetic hyperactivity, such as disorders in glucose metabolism.

Key words

resistant hypertension - diabetes - renal denervation - sympathetic activity

• Literatur

• 1 Heidmann C. Prevalence and temporal trend of known diabetes mellitus: results oft he German Health Interview and Examination Survey of Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 688-677
• 2 Meisinger C. Regional disparities of hypertension prevalence and mangement within Germany. J Hypertens 2006; 24: 293-299
• 3 Maier W. The Diabetes Collaborative Research of Epidemiologic Studies (DIAB-CORE) consortium. The impact of regional deprivation and individueal socio-ecoomic status on the prevalence of type 2 diabetes in Germany. Diabet Med 2012; 30: 78-86
• 4 Mancia G. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31: 1281-1357
• 5 Landgraf B. Praxisempfehlungen DDG/DGIM. Therapie des Typ-2-Diabetes. Diabetologie 2013; 8: 93-105
• 6 Mahfoud F. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresitenten Hypertonie. Dtsch Med Wochenschr 2011; 136: 2418-2424
• 7 Berndt C. Resilienz. Das Geheimnis der psychischen Widerstandskraft. DTV 2013; 15-22
• 8 Davis MI. Effectiness of renal denervation therapy for resistant hypertension. J Am Coll Cardiol 2013; 62: 231-241
• 9 Rippy MK. Cather-based renal sympathetic denervation. Clin Res Cardio 2011; 100: 1095-1001
• 10 Krum H. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle study. Lancet 2009; 373: 1275-1281
• 11 Böhm M. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol 2013; 10: 465-476
• 12 Johns EJ. Resistant hypertension and renal denervation: 3 Years on. Lancet 2014; 383: 583-584
• 13 Brandt MC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Card 2012; 59: 901-909
• 14 Pokushalov E. A radomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervaton in patients with refractory symptomatic arterial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-1170
• 15 Witkowski A. Effect of renal sympathetic denervation on blood pressure, sleep apnoe course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565
• 16 Mahfoud F. Effect of renal sympathetic denervation on glucose metabolism in patients with resitant hypertension: a pilot study. Circulation 2011; 18: 1940-1946
• 17 Schlaich MP. Renal denervation: a potential new treatment modality for polycyctic ovary syndrome?. J Hypertens 2011; 29: 991-996
• 18 Huang WC. Renal denervation prevents and reverses hyperinsulinemia-iduced hypertension in rats. Hypertension 1998; 32: 249-254
• 19 Bhatt DL. A controlled trialopf renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401